New Launch3 Nov 2026, 07:40 pm
Lupin Launches Raltegravir Tablets in US
AI Summary
Lupin Limited has announced the launch of Raltegravir Tablets USP, 600 mg in the United States, following U.S. FDA approval. This product is indicated for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adult and pediatric patients. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity. The reference listed drug, Isentress® HD Tablets, 600 mg, had an estimated annual sale of USD 26 million in the U.S. as of September 2026.
Key Highlights
- Lupin launches Raltegravir Tablets USP, 600 mg in the US.
- Product approved by the U.S. FDA for HIV-1 treatment.
- Lupin is the exclusive first-to-file, eligible for 180-day exclusivity.
- RLD had estimated annual sales of USD 26 million in the US.
Price Impact
More from LUPIN